Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 2
2007 2
2008 3
2009 5
2010 2
2011 3
2012 3
2013 4
2014 11
2015 4
2016 5
2017 14
2018 11
2019 15
2020 19
2021 23
2022 25
2023 24
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Tomizawa M, Shimizu T, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: torimoto k. J Chemother. 2024 Apr 17:1-13. doi: 10.1080/1120009X.2024.2340885. Online ahead of print. J Chemother. 2024. PMID: 38628149
Correction: Utility of a penile compression device for the quality of life in male patients with urinary incontinence after prostatectomy (the MORE study): a randomized prospective study.
Gotoh D, Torimoto K, Onishi K, Morizawa Y, Hori S, Nakai Y, Miyake M, Fujimoto K. Gotoh D, et al. Among authors: torimoto k. BMC Res Notes. 2024 Mar 12;17(1):73. doi: 10.1186/s13104-024-06732-9. BMC Res Notes. 2024. PMID: 38475880 Free PMC article. No abstract available.
Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Shimizu T, Miyake M, Nishimura N, Yoshida T, Itami Y, Tachibana A, Omori C, Oda Y, Kohashi M, Tomizawa M, Onishi K, Hori S, Morizawa Y, Dotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: torimoto k. Cancers (Basel). 2024 Feb 19;16(4):841. doi: 10.3390/cancers16040841. Cancers (Basel). 2024. PMID: 38398232 Free PMC article.
Long-term follow-up of congenital hydronephrosis in a single-center study.
Morizawa Y, Aoki K, Fukui S, Tomizawa M, Shimizu T, Onishi K, Hori S, Gotoh D, Nakai Y, Miyake M, Torimoto K, Fujimoto K, Otani T, Fujimoto K. Morizawa Y, et al. Among authors: torimoto k. Int J Urol. 2024 May;31(5):507-511. doi: 10.1111/iju.15391. Epub 2024 Jan 11. Int J Urol. 2024. PMID: 38205874
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group. Miyake M, et al. Among authors: torimoto k. Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. Jpn J Clin Oncol. 2024. PMID: 38061911
Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer.
Iemura Y, Miyake M, Fukui S, Fujii T, Ohnishi S, Hori S, Morizawa Y, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Iemura Y, et al. Among authors: torimoto k. Curr Urol. 2023 Dec;17(4):229-235. doi: 10.1097/CU9.0000000000000193. Epub 2023 Nov 3. Curr Urol. 2023. PMID: 37994338 Free PMC article.
158 results